Document Detail


The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction.
MedLine Citation:
PMID:  20557328     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A prospective, open-label, 3-month study was conducted to evaluate the feasibility and short-term clinical effect of subcutaneous erythropoietin injections in patients with anemia and heart failure with preserved ejection fraction (ejection fraction, 55%+/-2%). Using a dose-adjusted algorithm to effect a rate of rise in hemoglobin not to exceed 0.4 g/dL /wk, hemoglobin (10.8+/-0.3 to 12.2+/-0.3 g/dL) and red blood cell volume (1187+/-55 to 1333+/-38 mL) increased with an average weekly dose of 3926 units. Functional measures increased from baseline (6-minute walk test [289+/-24 to 331+/-22 m], exercise time [432+/-62 to 571+/-51 s], and peak oxygen consumption [8.2+/-0.7 to 9.4+/-0.9 mL/kg/min], all P<.05). End-diastolic volume declined significantly (8% volumetric decrease, 108+/-3 to 100+/-3 mL, P =.03), but there were no significant changes in left ventricular mass or estimated left ventricular end-diastolic pressure. Pressure-volume analysis demonstrated a reduction in ventricular capacitance at an end-diastolic pressure of 30 mm Hg without significant changes in contractile state.
Authors:
Rose S Cohen; Paula Karlin; Madeline Yushak; Donna Mancini; Mathew S Maurer
Related Documents :
2438948 - Contractility-dependent curvilinearity of end-systolic pressure-volume relations.
8376948 - Developmental changes in the acetylcholine influence on heart muscle of rana catesbeian...
24805148 - The sympathetic nervous system as a target for the treatment of hypertension and cardio...
1935158 - Systolic and diastolic time intervals in the critically ill patient.
8263888 - Prevalence of left ventricular hypertrophy as assessed by electrocardiogram in treated ...
24517108 - Efficacy and safety profile of aliskiren: practical implications for clinicians.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Congestive heart failure (Greenwich, Conn.)     Volume:  16     ISSN:  1751-7133     ISO Abbreviation:  Congest Heart Fail     Publication Date:    2010 May-Jun
Date Detail:
Created Date:  2010-06-18     Completed Date:  2011-06-02     Revised Date:  2014-09-10    
Medline Journal Info:
Nlm Unique ID:  9714174     Medline TA:  Congest Heart Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  96-103     Citation Subset:  IM    
Copyright Information:
(c) 2009 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptation, Psychological
Aged
Aged, 80 and over
Algorithms
Anemia / etiology*
Cardiac Output
Erythropoietin / therapeutic use*
Exercise Tolerance / drug effects*
Female
Health Status Indicators
Heart Failure / complications*,  ultrasonography
Hemodynamics
Humans
Male
Middle Aged
Oxygen Consumption
Prospective Studies
Quality of Life*
Questionnaires
Stroke Volume / drug effects
Time Factors
Ventricular Function, Left / drug effects
Ventricular Remodeling*
Grant Support
ID/Acronym/Agency:
K24 AG036778/AG/NIA NIH HHS; R01 AG027518/AG/NIA NIH HHS; R01 AG027518-04/AG/NIA NIH HHS; R01AG027518-01A1/AG/NIA NIH HHS
Chemical
Reg. No./Substance:
11096-26-7/Erythropoietin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of anemia with darbepoetin alfa in heart failure.
Next Document:  Low-dose dobutamine stress echocardiography to assess left ventricular contractile reserve for cardi...